Literature DB >> 23453859

Oculopharyngeal muscular dystrophy as a cause of progression of weakness in antibody positive myasthenia gravis.

Björn Oskarsson1, Steven P Ringel.   

Abstract

Many neuromuscular conditions cause bulbar and limb weakness, and when several conditions coexist they present additional diagnostic challenges. Here we describe a case of a 45-year-old woman with antibody positive myasthenia gravis since age 16, who then develops treatment-resistant weakness due to genetically proven oculopharyngeal muscular dystrophy. We conclude that the development of treatment-resistant weakness in myasthenia gravis should spur further work up for other neuromuscular disorders including oculopharyngeal muscular dystrophy.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23453859      PMCID: PMC4181576          DOI: 10.1016/j.nmd.2013.01.012

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  9 in total

1.  Temporal coincidence of myasthenia gravis and Guillain Barré syndrome associated with Hashimoto thyroiditis.

Authors:  Jing Ye Wang; Jie Pan; Ben Yan Luo; Yan Yan Zhang
Journal:  Neurol Sci       Date:  2011-04-14       Impact factor: 3.307

2.  Acetylcholine receptor antibodies in patients with genetic myopathies: clinical and biological significance.

Authors:  Russell J M Lane; Federico Roncaroli; Peter Charles; Dennis G McGonagle; Richard W Orrell
Journal:  Neuromuscul Disord       Date:  2011-08-26       Impact factor: 4.296

3.  Unusual occurrence of amyotrophic lateral sclerosis in myasthenia gravis.

Authors:  Karkal Ravishankar Naik; Aralikatte Onkarappa Saroja; Manik Mahajan
Journal:  Amyotroph Lateral Scler       Date:  2012-08-09

4.  Oculopharyngeal muscular dystrophy in Hispanic New Mexicans.

Authors:  M W Becher; L Morrison; L E Davis; W C Maki; M K King; J M Bicknell; B L Reinert; C Bartolo; D G Bear
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

5.  A case of polymyositis complicated with myasthenic crisis.

Authors:  Yoshito Yoshidome; Shinji Morimoto; Naoto Tamura; Shigeto Kobayashi; Hiroshi Tsuda; Hiroshi Hashimoto; Yoshinari Takasaki
Journal:  Clin Rheumatol       Date:  2006-10-18       Impact factor: 2.980

6.  Recent studies on oculopharyngeal muscular dystrophy in Québec.

Authors:  J P Bouchard; B Brais; D Brunet; P V Gould; G A Rouleau
Journal:  Neuromuscul Disord       Date:  1997-10       Impact factor: 4.296

7.  Unequal crossing-over in unique PABP2 mutations in Japanese patients: a possible cause of oculopharyngeal muscular dystrophy.

Authors:  Mika Nakamoto; Satoshi Nakano; Shingo Kawashima; Masafumi Ihara; Yo Nishimura; Akiyo Shinde; Akira Kakizuka
Journal:  Arch Neurol       Date:  2002-03

Review 8.  Treatment of autoimmune myasthenia gravis.

Authors:  David P Richman; Mark A Agius
Journal:  Neurology       Date:  2003-12-23       Impact factor: 9.910

9.  Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis.

Authors:  P K Panegyres; M Squier; K R Mills; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

  9 in total
  1 in total

1.  Oculopharyngeal muscular dystrophy misdiagnosed as myasthenia gravis: Case report and review of literature.

Authors:  Omid Aryani; Mohammadreza Akbari; Masoud Aghsaei-Fard; Arash Mirmohammad-Sadeghi; Samira Yadegari
Journal:  Iran J Neurol       Date:  2017-04-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.